Skip to main content

Invivyd, Inc.

corporate_fare Company Profile

Invivyd, Inc.

IVVD·NASDAQ·Life Sciences·CIK 0001832038

Invivyd, Inc. is a biopharmaceutical company that discovers, develops, and commercializes monoclonal antibody (mAb) therapies to prevent and treat serious viral infectious diseases. The company focuses on providing protection from these diseases, starting with SARS-CoV-2, the virus responsible for COVID-19. PEMGARDA® (pemivibart) is Invivyd's first mAb to receive regulatory authorization. On March 22, 2024, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for PEMGARDA injection, for intravenous (IV) use. This investigational mAb is authorized for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to specific medical conditions or immunosuppressive medications/treatments, and are unlikely to develop an adequate immune response to COVID-19 vaccination. Recipients must not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. The emergency use of PEMGARDA is authorized for the duration of the declaration justifying emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. The company aims to expand its mAb development into other high-need indications, such as respiratory syncytial virus (RSV) and measles.

Invivyd, Inc. (NASDAQ:IVVD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for IVVD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Pivotal COVID Drug Trial Fully Enrolls, IDMC Gives Positive Safety Nod; Invivyd Reports Doubled Revenue
  • Invivyd Reports Strong Q4 Revenue, $226.7M Cash, Advances VYD2311 to Phase 3 with Fast Track Designation

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$53.43M
Net Income
-$52.49M
Diluted EPS
-$0.30
Op. Cash Flow
-$58.13M
Free Cash Flow
-$58.29M
Operating Income
-$55.56M
Cash & Equivalents
$226.69M
Debt / Equity
0.00×
Net Margin
-98.2%
Shares Outstanding
281.99M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-092547
$0.43 +4.19% today
52-week range · as of 2026-11-16 $0.43 – $3.07
Market cap
$122.01M
Volume
5.3M (1.3× avg)
3-mo avg 4M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IVVD - Filings & News (Page 2)

IVVD
Mar 05, 2026, 7:03 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.76
Real-time Price: $0.430 info
Change: -$1.33 (-76%) info
Market Cap: $122.007M info
IVVD
Jan 08, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.48
Real-time Price: $0.430 info
Change: -$2.05 (-83%) info
Market Cap: $122.007M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets